Current News

Contact | Print version | Send article | RSS feed

Ryogen Licenses Human Aminopeptidase P Gene Patent to Invitrogen

15 Jan 2007 - Ryogen LLC announced that the company have entered into a nonexclusive license agreement with Invitrogen Corporation, whereby Invitrogen has licensed from Ryogen the patent directed to the clinically important Aminopeptidase P gene.
 
The US Patent (No. 6,399,349) titled "Human Aminopeptidase P Gene," which is the subject of the License Agreement, covers the XPNPEP2 gene sequenced by Dr. James Ryan, Chief Scientist of Ryogen LLC. XPNPEP2 codes for the membrane-bound aminopeptidase P (AmP). This protein is a significant marker for hypertension, angioedema, rejection of kidney transplants, certain tumors and other diseases. The patent covers the cDNA and gDNA sequences encoding AmP, a method of producing recombinant AmP, diagnostics for detecting AmP abnormalities, and prevention and treatment of medical conditions, associated with the mutation of the AmP gene.